This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| CYP3A4 | |
|---|---|
| Name | CYP3A4 |
| Ec number | 1.14.14.1 |
| Other names | Cytochrome P450 3A4 |
CYP3A4 is a human hepatic and intestinal monooxygenase of the cytochrome P450 superfamily that catalyzes oxidative metabolism of a large fraction of clinically used drugs. Discovered during investigations at institutions such as National Institutes of Health, CYP3A4 activity underpins pharmacokinetic variability observed in populations studied by groups like Food and Drug Administration and European Medicines Agency. Its role has been characterized in landmark clinical trials and pharmacology texts used at universities including Harvard University and Stanford University.
CYP3A4 performs NADPH-dependent monooxygenation reactions relevant to drug clearance, steroid biotransformation, and xenobiotic detoxification observed in clinical cohorts from hospitals such as Mayo Clinic and Johns Hopkins Hospital. Investigations reported by teams at Centers for Disease Control and Prevention and laboratories affiliated with University of California, San Francisco document CYP3A4-mediated metabolism of ligands initially profiled in screens developed at Pfizer, GlaxoSmithKline, and Roche. Its catalytic repertoire influences dosing recommendations issued by regulatory bodies like World Health Organization and therapeutic guidelines from organizations such as American College of Cardiology.
The CYP3A4 apoprotein architecture was elucidated through X-ray crystallography studies conducted by research groups at institutions like University of Pennsylvania and Scripps Research Institute, revealing a heme prosthetic group coordinated to the conserved cysteine residue first characterized in work linked to Max Planck Society scientists. Mechanistic proposals build on electron transfer models involving partners such as NADPH-dependent cytochrome P450 reductase and have been incorporated into biophysical analyses used at Cold Spring Harbor Laboratory and Massachusetts Institute of Technology. Structural plasticity enabling allosteric cooperativity has been compared to conformational studies from investigators at Imperial College London and ETH Zurich.
CYP3A4 expression is prominent in hepatocytes of liver specimens studied at Karolinska Institute and enterocytes from biopsy collections at Mayo Clinic and is transcriptionally regulated by nuclear receptors including Pregnane X receptor, Constitutive androstane receptor, and Vitamin D receptor, as shown in research funded by agencies like National Science Foundation. Induction and suppression have been profiled across clinical trials led by Cleveland Clinic and pharmacology consortia involving GlaxoSmithKline and Novartis, with epigenetic and microRNA influences investigated by teams at Cold Spring Harbor Laboratory and Broad Institute.
CYP3A4 metabolizes diverse substrates originally cataloged in drug libraries from Merck and AstraZeneca, including immunosuppressants evaluated in studies at Stanford University Medical Center, statins tested in trials at Mayo Clinic, and benzodiazepines examined in cohorts from National Institute of Mental Health. Potent inhibitors identified in clinical pharmacology reports from Food and Drug Administration submissions include compounds co-developed by Pfizer and Novartis, while classic inducers such as rifampicin were characterized in studies at London School of Hygiene & Tropical Medicine and University College London. Drug–drug interaction alerts citing CYP3A4 are incorporated into prescribing systems used by hospitals like Massachusetts General Hospital and regulatory advisories from European Medicines Agency.
Variability in CYP3A4 activity affects therapeutic outcomes documented in multicenter trials coordinated by National Heart, Lung, and Blood Institute and oncology studies at MD Anderson Cancer Center. Although CYP3A4 polymorphisms are less predictive than variants in genes such as those studied by 1000 Genomes Project, its clinical implications intersect with precision medicine initiatives at Mayo Clinic Center for Individualized Medicine and pharmacogenomic guidelines developed by groups like the Clinical Pharmacogenetics Implementation Consortium. Drug labeling revisions informed by CYP3A4 considerations have been issued by Food and Drug Administration and reflected in formularies maintained by institutions such as Johns Hopkins Hospital.
In vitro and in vivo assays for CYP3A4 activity employ probe substrates recommended in methodological papers from laboratories at Scripps Research Institute and University of Oxford, using chromatographic platforms commercialized by companies like Agilent Technologies and Thermo Fisher Scientific. Phenotyping approaches include midazolam clearance studies executed in clinical pharmacology units at Vanderbilt University Medical Center and high-throughput screens developed in collaborations with GlaxoSmithKline and Pfizer. Regulatory bioanalytical guidance incorporating CYP3A4 assay standards has been issued by European Medicines Agency and Food and Drug Administration.
CYP3A4 belongs to an evolutionarily conserved subfamily related to CYP3A5 and CYP3A7, with comparative genomics analyses performed by groups at Wellcome Sanger Institute and Broad Institute revealing orthologs in mammalian species studied at University of Cambridge and Max Planck Institute for Evolutionary Anthropology. Phylogenetic reconstructions referencing databases curated by National Center for Biotechnology Information and Ensembl trace gene duplication events examined in evolutionary biology work at University of Oxford and Harvard University.
Category:Human proteins